Herd immunity: Recent uses in vaccine assessment

Expert Review of Vaccines

Volumn 7, Issue 10, 2008, Pages 1493-1506

  Gonçalves, Guilherme ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b Centro de Saúde de Vila Nova de Famalicão   (Portugal)

Author keywords

Community immunity; Herd effect; Herd immunity; Herd immunity threshold; Herd protection; Vaccination

Indexed keywords

CHICKENPOX VACCINE; CHOLERA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; INFLUENZA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MUMPS VACCINE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RUBELLA VACCINE; TETANUS TOXOID; VACCINE; WART VIRUS VACCINE;

CHICKENPOX; CHOLERA; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE COST; HEALTH PROGRAM; HEPATITIS A; HERD IMMUNITY; HUMAN; INFLUENZA; MEASLES; MENINGOCOCCOSIS; MUMPS; NATURAL SELECTION; NONHUMAN; PERTUSSIS; POLIOMYELITIS; PREDATOR; PREY; PRIORITY JOURNAL; REVIEW; RUBELLA; UTERINE CERVIX CANCER; VACCINATION;

HUMANS; IMMUNITY, HERD; VACCINES;

EID: 57349150641     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.10.1493     Document Type: Review

References (143)

1. Berger A. How does herd immunity work? BMJ 319, 1466-1467 (1999).
2. Fox JP, Helveback L, Scott W, Gatewood L, Ackerman E. Herd immunity: basic concept and relevance to public health immunization practices. Am. J. Epidemiol. 94(3), 179-189 (1971). •• First review on herd immunity. A seminal article, so considered by subsequent review papers.
3. Fine PEM, Mulholland K. Community immunity. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA (Eds). Saunders, Elsevier, PA, USA 1573-1592 (2008). •• The authors developed the basic ideas of a review paper published in 1993 and the previous edition of this book. New knowledge and new vaccines make it particularly rich. This text is an outstanding document.
4. John TJ, Samuel R. Herd immunity and herd effect: new insights and definitions. Eur. J. Epidemiol. 16(7), 601-606 (2000). • The authors were especially concerned with the different uses of the term 'herd immunity'. The revision of previous definitions and the proposal of new ones is a good insight search on the subject.
5. Forte WN. Imunologia básica e aplicada. ARTMED® Editora S.A., Porto Alegre, Brasil (2004).
6. Ada G. The immunology of vaccination. In: Vaccines (4th Edition). Plotkin SA, Orenstein WA (Ed.). Saunders Elsevier, PA, USA 31-45 (2004).
7. Anderson RM. The concept of herd immunity and the design of community-based immunization programmes. Vaccine 10(13), 928-935 (1992). •• Emphasis is placed on mathematical models as a tool to understand the effects of herd immunity.
8. Fine PEM. Herd immunity: history, theory and practice. Epidemiol. Rev. 15, 265-302 (1993). •• A cornerstone on the subject.
9. Fine PEM. Community immunity. In: Vaccines (4th Edition). Plotkin SA, Orenstein WA (Eds). Saunders Elsevier, PA, USA 1443-1461 (2004). • The author developed the basic ideas of the review paper published in 1993, but with new insights.
10. Mühlemann K, Weiss NS. Can herd immunity influence the assessment of vaccine efficacy in nonrandomized studies? Am. J. Public Health 87(1), 113-114 (1997).
11. Paul Y. Herd immunity and herd protection. Vaccine 22(3-4), 301-302 (2004). •• Very important letter to the editor. The authors addressed the recurrent problem of the different uses of the term 'herd immunity'. While new definitions were proposed, a clearer view emerged.
12. Tennenbaum S. Simple criteria for finding (nearly) optimal vaccination strategies. J. Theor. Biol. 250(4), 673-683 (2008).
13. Last JM (Ed.). A Dictionary of Epidemiology. (4th Edition). Oxford University Press, Oxford, UK (2001).
14. Maia JOC. Some mathematical developments of the epidemic theory formulated by Reed and Frost. Hum. Biol. 24, 167-200 (1952).
15. Popper KR. Unended Quest: an Intellectual Autobiography. Routledge, UK (2002).
16. Ferrari MJ, Bansal S, Meyers LA, Bjørnstad ON. Network frailty and the geometry of herd immunity. Proc. Biol. Sci. 273(1602), 2743-2748 (2006).
17. Bauch CT. Imitation dynamics predict vaccinating behaviour. Proc. Biol. Sci. 272(1573), 1669-1675 (2005).
18. Cojocaru MG, Bauch CT, Johnston MD. Dynamics of vaccination strategies via projected dynamical systems. Bull. Math. Biol. 69(5), 1453-1476 (2007).
19. Boëlle PY. Theoretical epidemiology and vaccine. Rev. Med. Interne 28(3), 161-165 (2007).
20. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 26(3), 191-215 (2008).
21. Pradas-Velasco R, Antoñanzas-Villar F, Martínez- Zárate MP. Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination. Pharmacoeconomics 26(1), 45-56 (2008).
22. Szucs TD. Health economic research on vaccinations and immunisation practices - an introductory primer. Vaccine 23(17-18), 2095-2103 (2005).
23. Dawson A. Vaccination and the prevention problem. Bioethics 18(6), 515-530 (2004).
24. May T, Silverman RD. Free-riding, fairness and the rights of minority groups in exemption from mandatory childhood vaccination. Hum. Vaccin. 1(1), 12-15 (2005).
25. Calandrillo SP. Vanishing vaccinations: why are so many Americans opting out of vaccinating their children? Univ. Mich. J. Law Reform 37(2), 353-440 (2004).
26. Dawson A. What are the moral obligations of the traveller in relation to vaccination? Travel. Med. Infect. Dis. 5(2), 90-96 (2007).
27. Verweij MF, van den Hoven MA. Influenza vaccination in Dutch nursing homes: is tacit consent morally justified? Med. Health Care Philos. 8(1), 89-95 (2005).
28. Kahn J. What vaccination programs mean for research. Am. J. Bioeth. 7(3), 3-4 (2007).
29. Congeni BL. Vaccine shortages eliminate possibility for excess capacity in stockpiles. Pediatr. Ann. 33(9), 577-583 (2004).
30. McIntosh ED. Paediatric infections: prevention of transmission and disease - implications for adults. Vaccine 23(17-18), 2087-2089 (2005).
31. Elliott C, Farmer K. Immunization status of children under 7 years in the Vikas Nagar area, North India. Child Care Health Dev. 32(4), 415-421 (2006).
32. Menzies R, McIntyre P. Vaccine preventable diseases and vaccination policy for indigenous populations. Epidemiol. Rev. 28, 71-80 (2006).
33. Heymann DL, Aylward RB. Mass vaccination: when and why. Curr. Top. Microbiol. Immunol. 304, 1-16 (2006).
34. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J. Infect. Dis. 191(Suppl. 1), S97-S106 (2005).
35. Schellekens J, von König CH, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr. Infect. Dis J. 24(5 Suppl.), S19-S24 (2005).
36. Tan T, Halperin S, Cherry JD et al. Pertussis immunization in the global pertussis initiative North American region: recommended strategies and implementation considerations. Pediatr. Infect. Dis. J. 24(5 Suppl.), S83-S86 (2005).
37. Esen B, Coplu N, Kurtoglu D, Gozalan A, Akin L. Prevalence of high antibody titers of pertussis in Turkey: reflection of circulating microorganism and a threat to infants. J. Clin. Lab. Anal. 21(3), 154-161 (2007).
38. Lee GM, Murphy TV, Lett S et al. Cost effectiveness of pertussis vaccination in adults. Am. J. Prev. Med. 32(3), 186-193 (2007).
39. Casey JR, Pichichero ME. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. Drugs 65(10), 1367-1389 (2005).
40. Pichichero ME, Casey JR. Acellular pertussis vaccines for adolescents. Pediatr. Infect. Dis. J. 24(6 Suppl.), S117-S126 (2005).
41. Pósfay-Barbe KM. Whooping cough: a diagnosis one shouldn't forget. Rev. Med. Suisse 2(54), 503-506, 509-511 (2006).
42. Byrne S, Slack AT. Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003. BMC Infect. Dis. 6, 53 (2006).
43. Gomes MG, White LJ, Medley GF. The reinfection threshold. J. Theor. Biol. 235(2), 151-152 (2005).
44. Águas R, Gonçalves G, Gomes MGM. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infect. Dis. 6, 112-117 (2006).
45. Robbins JB, Schneerson R, Keith JM, Shiloach J, Miller M, Trollors B. The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP. Vaccine 25(15), 2811-2816 (2007).
46. Caro JJ, Getsios D, El-Hadi W, Payne K, O'Brien JA. Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr. Infect. Dis. J. 24(5 Suppl.), S75-S82 (2005).
47. Ali M, Emch M, Yunus M, Sack D et al. Vaccine protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission. Pediatr. Infect. Dis. J. 27(1), 33-37 (2008).
48. Longini IM Jr, Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD. Controlling endemic cholera with oral vaccines. PLoS Med. 4(11), e336 (2007).
49. Sánchez J, Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr. Opin. Immunol. 17(4), 388-398 (2005).
50. Makwana N, Riordan FA. Bacterial meningitis: the impact of vaccination. CNS Drugs 21(5), 355-366 (2007).
51. Zhang Q, Finn A. Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria. J. Clin. Pathol. 57(10), 1015-1021 (2004).
52. Miranzi Sde S, Moraes SA, Freitas IC. Trends in Haemophilus influenzae type b meningitis in Brazil in children under five years of age from 1983 through 2002. Rev. Soc. Bras. Med. Trop. 39(5), 473-477 (2006).
53. Ladhani S, Slack MP, Heys M, White J, Ramsay ME. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch. Dis. Child. 93, 665-669 (2007).
54. Bauch CT, Anonychuk AM, Pham BZ, Gilca V, Duval B, Krahn MD. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine 25(51), 8536-8548 (2007).
55. André FE. Universal mass vaccination against hepatitis A. Curr. Top. Microbiol. Immunol. 304, 95-114 (2006).
56. Lopez E, Debbag R, Coudeville L, Baron-Papillon F, Armoni J. The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health - economic analysis. J. Gastroenterol. 42(2), 152-160 (2007).
57. Genton B, D'Acremont V, Furrer HJ, Hatz C, Loutan L. Hepatitis A vaccines and the elderly. Travel. Med. Infect. Dis. 4(6), 303-312 (2006).
58. Hollinger FB, Bell B, Levy-Bruhl D, Shouval D, Wiersma S, Van Damme P. Hepatitis A and B vaccination and public health. J. Viral. Hepat. 14(Suppl. 1), 1-5 (2007).
59. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 294(2), 202-210 (2005).
60. Domínguez A, Oviedo M, Carmona G et al. Impact and effectiveness of a mass hepatitis A vaccination programme of preadolescents seven years after introduction. Vaccine 26(14), 1737-1741 (2008).
61. Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol. Rev. 28, 101-111 (2006).
62. Van Effelterre TP, Zink TK, Hoet BJ, Hausdorff WP, Rosenthal P. A mathematical model of hepatitis a transmission in the United States indicates value of universal childhood immunization. Clin. Infect. Dis. 43(2), 158-164 (2006).
63. Armstrong GL, Billah K, Rein DB, Hicks KA, Wirth KE, Bell BP. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity. Pediatrics 119(1), e22-e29 (2007).
64. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylatic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 177(5), 469-479 (2007).
65. Cutts FT, Fransceschi S, Goldie S et al. Human papillomavirus and HPV vaccines: a review. Bull. WHO 85(9), 719-716 (2007).
66. Lippman A, Boscoe M, Scurfield C. Do you approve of spending $300 million on HPV vaccination? No. Can. Fam. Physician 54, 175-177 (2008).
67. Regan DG, Philp DJ, Hocking JS, Law MG. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex. Health 4(3), 147-163 (2007).
68. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol. Rev. 28, 88-100 (2006).
69. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg. Infect. Dis. 14(2), 244-251 (2008).
70. Kulasingam S, Connelly L, Conway E et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex. Health 4(3), 165-175 (2007).
71. Piedra PA, Gaglani MJ, Kozinetz CA et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 23(13), 1540-1548 (2005).
72. Piedra PA, Gaglani MJ, Kozinetz CA et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 120(3), e553-e564 (2007).
73. Schwartz B, Hinman A, Abramson J et al. Universal influenza vaccination in the United States: are we ready? Report of a meeting. J. Infect. Dis. 194(Suppl. 2), S147-S154 (2006).
74. Chantler T, Pace D, Wright A et al. Uptake and acceptability of influenza vaccination in day nursery children. Community Pract. 80(12), 32-36 (2007).
75. Wu JT, Riley S, Leung GM. Spatial considerations for the allocation of pre-pandemic influenza vaccination in the United States. Proc. Biol. Sci. 274(1627), 2811-2817 (2007).
76. Saffar MJ, Amiri-Alreza M, Baba-Mahmoodi F, Saffar H. Measles epidemiology in Mazandaran province, Iran, 2000-2002. Trop. Doct. 37(1), 30-32 (2007).
77. Rentsen T, Enkhtuya B, Nymadawa P et al. Measles outbreak after a post-honeymoon period in Mongolia, 2001. Jpn. J. Infect. Dis. 60(4), 198-199 (2007).
78. Hyde TB, Dayan GH, Langidrik JR et al. Measles outbreak in the Republic of the Marshall Islands, 2003. Int. J. Epidemiol. 35(2), 299-306 (2006).
79. Ong G, Hoon HB, Ong A, Chua LT, Kai CS, Tai GK. A 24-year review on the epidemiology and control of measles in Singapore, 1981-2004. Southeast Asian J. Trop. Med. Public Health 37(1), 96-101 (2006).
80. Friederichs V, Cameron JC, Robertson C. Impact of adverse publicity on MMR vaccine uptake: a population based analysis of vaccine uptake records for one million children, born 1987-2004. Arch. Dis. Child. 91(6), 465-468 (2006).
81. Wallinga J, Heijne JC, Kretzschmar M. A measles epidemic threshold in a highly vaccinated population. PLoS Med. 2(11), e316 (2005).
82. Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine 24(22), 4692-4700 (2006).
83. Maiden MC, Ibarz-Pavón AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197(5), 737-743 (2008).
84. Borrow R, Miller E. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev. Vaccines 5(6), 851-857 (2006).
85. Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am. J. Epidemiol. 162(1), 89-100 (2005).
86. Ortega-Sanchez IR, Meltzer MI, Shepard C et al. Active Bacterial Core Surveillance Team. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin. Infect. Dis. 46(1), 1-13 (2008).
87. Caro JJ, Möller J, Getsios D et al. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. BMC Public Health 7(147), 130 (2007).
88. De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, Nguyen VH. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. Vaccine 25(29), 5433-5440 (2007).
89. Trotter CL, Edmunds WJ. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med. Decis. Making 26(1), 38-47 (2006).
90. Hviid A, Rubin S, Mühlemann K. Mumps. Lancet 371(9616), 932-944 (2008).
91. Muhsen Kh, Aboudy Y, Mendelson E, Green MS, Cohen D. Prevalence of mumps antibodies in the Israeli population in relation to mumps vaccination policy and incidence of disease. Epidemiol. Infect. 136(5), 688-693 (2008).
92. Donaghy M, Cameron JC, Friederichs V. Increasing incidence of mumps in Scotland: options for reducing transmission. J. Clin. Virol. 35(2), 121-129 (2006).
93. Gijalva CG, Griffin MR. Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA. Expert Rev. Vaccines 7(1), 83-95 (2008).
94. Pebody RG, Leino T, Nohynek H, Hellenbrand W, Salmaso S, Ruutu P. Pneumococcal vaccination policy in Europe. Euro. Surveill. 10(9), 174-178 (2005).
95. Haber M, Barskey A, Baughman W et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine 25(29), 5390-5398 (2007).
96. Clarke SC, Jefferies JM, Smith AJ, McMenamin J, Mitchell TJ, Edwards GF. Potential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in Scotland. J. Clin. Microbiol. 44(4), 1224-1228 (2006).
97. Claes C, Reinert RR, von der Schulenburg JM. Cost-effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur. J. Health. Econ. DOI: 10.1007/s10198-008-0098-1 (2008) (Epub ahead of print).
98. Isaacman DJ, Strutton DR, Kalpas EA et al. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clin. Ther. 30(2), 341-357 (2008).
99. Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur. J. Health Econ. 9(1), 7-15 (2008).
100. Hubben GA, Bos JM, Glynn DM, van der Ende A, van Alphen L, Postma MJ. Enhanced decision support for policy makers using a web interface to health-economic models - illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in The Netherlands. Vaccine 25(18), 3669-3678 (2007).
101. Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination - a review (2002-2006). Vaccine 25(8), 1355-1367 (2007).
102. Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr. Infect. Dis. J. 25(6), 494-501 (2006).
103. McIntosh ED, Conway P, Willingham J, Hollingsworth R, Lloyd A. Pneumococcal pneumonia in the UK - how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine 23(14), 1739-1745 (2005).
104. Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 22(31-32), 4203-4214 (2004).
105. Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int. J. Antimicrob. Agents 32, 199-206 (2008).
106. O'Brien KL, Millar EV, Zell ER et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J. Infect. Dis. 196(8), 1211-1220 (2007).
107. Vila-Córcoles A. Advances in pneumococcal vaccines: what are the advantages for the elderly? Drugs Aging 24(10), 791-800 (2007).
108. Benninger MS. Acute bacterial rhinosinusitis and otitis media: changes in pathogenicity following widespread use of pneumococcal conjugate vaccine. Otolaryngol. Head Neck Surg. 138(3), 274-278 (2008).
109. Lipsitch M, O'Neill K, Cordy D et al. Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine. J. Infect. Dis. 196(8), 1221-1227 (2007).
110. Dagan R. The potential effect of widespread use of pneumococcal conjugate vaccines on the practice of pediatric otolaryngology: the case of acute otitis media. Curr. Opin. Otolaryngol. Head Neck Surg. 12(6), 488-494 (2004).
111. Adamkiewicz TV, Silk BJ, Howgate J et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics 121(3), 562-569 (2008).
112. Tasslimi A, Wenger P, Pentakota SR, Brimacombe M, Burday M, Sinha A. Invasive pneumococcal disease in an underimmunized, high HIV prevalence population. J. Infect. 56(2), 99-102 (2008).
113. Fletcher MA, Laufer DS, McIntosh ED, Cimino C, Malinoski FJ. Controlling invasive pneumococcal disease: is vaccination of at-risk groups sufficient? Int. J. Clin. Pract. 60(4), 450-456 (2006).
114. Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal disease. Curr. Opin. Infect. Dis. 20(1), 11-15 (2007).
115. Mackenzie G, Carapetis J, Leach AJ, Hare K, Morris P. Indirect effects of childhood pneumococcal vaccination on pneumococcal carriage among adults and older children in Australian Aboriginal communities. Vaccine 25(13), 2428-2433 (2007).
116. Käyhty H, Auranen K, Nohynek H, Dagan R, Mäkelä H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev. Vaccines 5(5), 651-667 (2006).
117. Metlay JP, Fishman NO, Joffe M, Edelstein PH. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine 24(4), 468-475 (2006).
118. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb. Mortal. Wkly Rep. 54(36), 893-897 (2005).
119. Shafinoori S, Ginocchio CC, Greenberg AJ, Yeoman E, Cheddie M, Rubin LG. Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Pediatr. Infect. Dis. J. 24(1), 10-16 (2005).
120. McClure CA, Ford MW, Wilson JB, Aramini JJ. Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: recommendations and expected benefits. Can. J. Infect. Dis. Med. Microbiol. 17(1), 19-26 (2006).
121. Black S, Shinefield H, Baxter R et al. Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine 24(Suppl. 2), S79-S80 (2006).
122. Poehling KA, Talbot TR, Griffin MR et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295(14), 1668-1674 (2006).
123. Isaacman DJ, Fletcher MA, Fritzell B, Ciuryla V, Schranz J. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar). Vaccine 25(13), 2420-2427 (2007).
124. Watson M, Roche P, Bayley K et al. Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine program. Commun. Dis. Intell. 28(4), 455-464 (2004).
125. Ho CF, Lin TY. Pneumococcal vaccines. Chang. Gung. Med. J. 28(11), 765-772 (2005).
126. Temime L, Dab W. Pneumococcal vaccination: expected benefits in adults. Rev. Med. Interne 28(1), 9-15 (2007).
127. Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297(16), 1784-1792 (2007).
128. Dias R, Caniça M. Invasive pneumococcal disease in Portugal prior and after the introduction of pneumococcal heptavalent conjugate vaccine. FEMS Immunol. Med. Microbiol. 51, 25-42 (2007).
129. Iwai M, Takizawa T, Nakayama T et al. Evaluation of a two-dose administration of live oral poliovirus vaccine for wild and virulent vaccine-derived poliovirus type 1, 2, 3 strains in Japan. Scand. J. Infect. Dis. 40(3), 247-253 (2008).
130. Gidding HF, Backhouse JL, Gilbert GL, Burgess MA. National serosurvey of poliovirus immunity in Australia, 1996-1999. Aust. NZ J. Public Health 29(1), 48-52 (2005).
131. Frantzidou F, Diza E, Halkia D, Antoniadis A. A seroprevalence study of poliovirus antibody in the population of northern Greece. Clin. Microbiol. Infect. 11(1), 68-71 (2005).
132. Wang IJ, Huang LM, Chen HH, Hwang KC, Chen CJ. Seroprevalence of rubella infection after national immunization program in Taiwan: vaccination status and immigration impact. J. Med. Virol. 79(1), 97-103 (2007).
133. Huerta M, Davidovitch N, Ankol OE et al. Declining seroprevalence of rubella antibodies among young Israeli adults: a 12-year comparison. Prev. Med. 39(6), 1223-1226 (2004).
134. Dashraath P, Ong ES, Lee VJ. Seroepidemiology of varicella and the reliability of a self-reported history of varicella infection in Singapore military recruits. Ann. Acad. Med. Singapore 36(8), 636-641 (2007).
135. Marcitelli R, Bricks LF. Varicella zoster in children attending day care centers. Clinics 61(2), 147-152 (2006).
136. Marin M, Watson TL, Chaves SS et al. Varicella among adults: data from an active surveillance project, 1995-2005. J. Infect. Dis. 197(Suppl. 2), S94-S100 (2008).
137. Lopez AS, Guris D, Zimmerman L et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics 117(6), e1070-e1077 (2006).
138. Quian J, Rüttimann R, Romero C et al. Impact of universal varicella vaccination of one year-olds in Uruguay: 1997-2005. Arch. Dis. Child. 93, 845-850 (2008).
139. Heininger U, Seward JF. Varicella. Lancet 368(9544), 1365-1376 (2006).
140. Nardone A, de Ory F, Carton M et al. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 25(45), 7866-7872 (2007).
141. Gonçalves G. Incerteza e Riscos em Epidemiologia e Saúde Pública. In: Encontro de Saberes. Três Gerações de Bolseiros da Gulbenkian. Tostões A, Arantes e Oliveira ER, Paixão JMP, Magalhães P (Eds). Fundação Calouste Gulbenkian, Lisbon, Portugal 455-471 (2006).
142. Last JM. Epidemiology and public health. In: Teaching Epidemiology. A Guide for Teachers in Epidemiology, Public Health and Clinical Medicine (2nd Edition). Olsen J, Saracci R, Trichopoulos D (Eds). Oxford University Press, Oxford, UK, 21-32 (2001).
143. ECDC. Guidance for the introduction of HPV vaccines in EU countries. Guidance Report. Stockholm, January 2008 http://www.ecdc.europa.eu/pdf/ HPV_report.pdf